MoonLake Immunotherapeutics (MLTX) investor relations material

Executive summary

• Advancing sonelokimab (SLK), a tri-specific IL-17A/F Nanobody, for inflammatory diseases with multiple late-stage clinical trials in HS, PsA, PPP, and axSpA; positive FDA pre-BLA meeting for HS, aligning on submission and label strategy, including adolescent data.

• No products approved or revenue from product sales; operations funded by equity and debt financings.

• BLA submission for SLK in HS expected end of September/Q3 2026, with potential Priority Review decision by end of November 2026 and US commercial launch in H2 2027, pending FDA approval.

Financial highlights

• Net loss of $69.7 million for Q1 2026, up 71.9% year-over-year; net loss per share $(0.98); cash, cash equivalents, and short-term marketable securities totaled $357.9 million as of March 31, 2026.

• Operating expenses rose 47.5% to $70.0 million, driven by R&D and G&A increases, including $13.4 million in share-based compensation, notably from voluntary cancellation of unvested options.

• R&D expenses: $54.5 million in Q1 2026; G&A expenses: $15.5 million in Q1 2026, up from $9.2 million in Q4 2025.

• Cash used in operations was $66.3 million for Q1 2026, up from $38.1 million in Q1 2025.

• No revenue recognized; all expenses related to R&D and G&A.

Outlook and guidance

• Sufficient capital to fund operations and planned capital expenditures through end of 2027, including completion of ongoing clinical trials and BLA submission; up to $400 million in additional non-dilutive funds available via Hercules Capital debt facility.

• Expect continued substantial operating losses for at least the next two years as clinical development and commercialization preparations continue.

• Additional capital may be required for commercialization or if clinical timelines extend.

• Key 2026 milestones: 52-week data from VELA-1 and VELA-2 HS trials (Q2), primary endpoint readouts for IZAR-1 (PsA) and VELA-TEEN (adolescent HS) in mid-2026, BLA submission in September, and IZAR-2 (PsA) readout in Q4.